Liftstream is an executive search recruitment company in the life sciences sector
5 Trends in Oncology Drug Development for 2012 and Beyond!
Oncology drug development is one of the largest areas within the pharmaceutical industry, addressing a disease area that causes more deaths than all other diseases apart from cardiovascular. The current global oncology market is estimated to be in the region of $55bn and forecast to grow to over $70bn by 2016. The oncology market is often seen as the most diverse with a wide range of indications and there are some 900 estimated clinical programmes currently underway. It is estimated that there are more than 200 different forms of cancer and therefore the oncology market presents a unique set of challenges to the industry.
Posted in General, Pharmaceutical business
Tagged Adaptive clinical trials, Antibodies, Antibody-drug conjugates, AstraZeneca, beyond borders, biomarkers, Blurprint medicine, breast cancer, cancer, Cancer Research UK, companion diagnostics, diagnostics, drug development, ernst & young, FDA, Genentech, Mark Levin, oncology, personalised medicine, Roche, seattle genetics, Third Rock Ventures, Tufts Center
1 Comment